Oncotelic Therapeutics Advances Cancer Research with AI and Nanomedicine Pipeline

Oncotelic Therapeutics, Inc. (OTCQB: OTLC) has been featured in a NetworkNewsWire editorial highlighting the company's innovative approach to addressing deadly cancers and rare pediatric disorders. The editorial emphasizes the urgent need for medical innovation in treating conditions such as glioblastoma and pancreatic cancer, where current treatment options remain limited.

Under the leadership of chair and CEO Dr. Vuong Trieu, Oncotelic is building a transformative pipeline that leverages artificial intelligence, nanomedicine, and advanced clinical strategies. The company's robust intellectual property portfolio includes approximately 500 patent applications and 75 granted patents, providing a strong foundation for its research and development efforts. This extensive patent protection supports the company's mission to reshape treatment approaches for cancer and rare diseases.

Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on developing oncology and immunotherapy products. The company targets high-unmet-need cancers and rare pediatric indications with late-stage therapeutic candidates. Beyond its internally developed drug pipeline, Oncotelic benefits from the inventions created by Dr. Trieu, who has filed more than 150 patent applications and holds 39 issued U.S. patents.

The company maintains strategic partnerships through joint ventures, including owning 45% of GMP Bio, a joint venture advancing complementary drug candidates under Dr. Trieu's leadership. This collaborative approach strengthens Oncotelic's position in oncology and rare disease therapeutics. Additional information about the company is available at https://nnw.fm/OTLC.

NetworkNewsWire, the publisher of the editorial featuring Oncotelic, is a specialized communications platform focused on financial news and content distribution for public and private companies. As part of the Dynamic Brand Portfolio, NNW provides comprehensive corporate communications solutions including wire distribution, editorial syndication, and social media outreach. The platform serves clients across diverse industries, helping them reach investors, journalists, and the general public through targeted content distribution.